Q2 EPS Forecast for Avalo Therapeutics Boosted by Analyst

Posted by George Bondi on May 19th, 2026

Avalo Therapeutics, Inc. (NASDAQ:AVTX – Free Report) – Stock analysts at HC Wainwright lifted their Q2 2026 earnings per share (EPS) estimates for shares of Avalo Therapeutics in a research note issued to investors on Thursday, May 14th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings per share of ($0.59) for the quarter, up from their prior estimate of ($1.04). HC Wainwright has a “Buy” rating and a $35.00 price objective on the stock. The consensus estimate for Avalo Therapeutics’ current full-year earnings is ($3.00) per share. HC Wainwright also issued estimates for Avalo Therapeutics’ Q3 2026 earnings at ($0.37) EPS, Q4 2026 earnings at ($0.39) EPS, FY2026 earnings at ($2.02) EPS, Q1 2027 earnings at ($0.39) EPS, Q2 2027 earnings at ($0.43) EPS, Q3 2027 earnings at ($0.45) EPS, Q4 2027 earnings at ($0.50) EPS and FY2027 earnings at ($1.78) EPS.

Avalo Therapeutics (NASDAQ:AVTX – Get Free Report) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.98) EPS for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.02.

A number of other research analysts have also commented on AVTX. Guggenheim assumed coverage on Avalo Therapeutics in a research report on Monday, February 2nd. They issued a “buy” rating and a $50.00 price objective on the stock. Citigroup reiterated an “outperform” rating on shares of Avalo Therapeutics in a research report on Wednesday, May 6th. Wolfe Research started coverage on Avalo Therapeutics in a research report on Thursday, April 9th. They issued an “outperform” rating and a $48.00 price objective on the stock. Wedbush cut their price target on Avalo Therapeutics from $40.00 to $34.00 and set an “outperform” rating on the stock in a research note on Thursday, May 14th. Finally, Wall Street Zen raised Avalo Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Sunday, March 29th. Eleven analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $48.13.

Get Our Latest Analysis on AVTX

Avalo Therapeutics Stock Performance

Shares of AVTX opened at $16.16 on Tuesday. The firm has a market capitalization of $473.91 million, a price-to-earnings ratio of -2.96 and a beta of 0.78. The business’s fifty day moving average price is $15.80 and its two-hundred day moving average price is $16.43. Avalo Therapeutics has a 52 week low of $3.43 and a 52 week high of $24.27.

Insider Activity

In other news, CFO Christopher Ryan Sullivan sold 8,458 shares of the stock in a transaction on Wednesday, April 29th. The stock was sold at an average price of $13.09, for a total value of $110,715.22. Following the transaction, the chief financial officer owned 8,880 shares of the company’s stock, valued at $116,239.20. This represents a 48.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mittie Doyle sold 25,492 shares of the stock in a transaction on Monday, March 16th. The shares were sold at an average price of $16.15, for a total value of $411,695.80. Following the completion of the transaction, the insider directly owned 3,622 shares in the company, valued at approximately $58,495.30. This trade represents a 87.56% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 138,078 shares of company stock valued at $2,501,346 in the last 90 days. 4.46% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. BIT Capital GmbH acquired a new stake in Avalo Therapeutics during the 3rd quarter worth $25,000. PFS Partners LLC raised its stake in Avalo Therapeutics by 100.0% during the 4th quarter. PFS Partners LLC now owns 2,000 shares of the company’s stock worth $36,000 after buying an additional 1,000 shares during the period. Boothbay Fund Management LLC acquired a new stake in Avalo Therapeutics during the 2nd quarter worth $56,000. Dimensional Fund Advisors LP acquired a new stake in Avalo Therapeutics during the 3rd quarter worth $143,000. Finally, AlphaCentric Advisors LLC acquired a new stake in Avalo Therapeutics during the 1st quarter worth $174,000. Institutional investors and hedge funds own 87.06% of the company’s stock.

Avalo Therapeutics News Roundup

Here are the key news stories impacting Avalo Therapeutics this week:

Positive Sentiment: HC Wainwright kept a Buy rating on Avalo Therapeutics and reiterated a $35 price target, signaling confidence in the company’s longer-term upside.
Positive Sentiment: The firm raised its earnings estimates for several periods, including FY2026 to ($2.02) per share and FY2027 to ($1.78) per share, suggesting improving expectations versus prior forecasts.
Positive Sentiment: HC Wainwright also significantly improved its Q4 2026, Q3 2026, and Q2 2026 EPS estimates, which can be read as a more constructive view on Avalo’s outlook.
Neutral Sentiment: The updates are research-note revisions, not a company announcement, so they may influence sentiment but do not by themselves change Avalo’s fundamentals. AVTX stock page
Negative Sentiment: Despite the upgrades, Avalo is still projected to lose money across the forecast period, with consensus FY2025 earnings at about ($3.00) per share, underscoring ongoing profitability risk.

Avalo Therapeutics Company Profile

(Get Free Report)

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.